ARPC: 3 -12 months to mRNA vaccine productions!, page-2

this could be months away, but at the mean time, the most traditional vaccine can fill the gap.

so I went back to seek and had another look of what they advertised, and they asked for people who has experience in fill and finish.

connecting the dots - biocelect is in charge of rollout novavax, who happens to be sharing an office with sandon capital the largest shareholder of idt, and idt is recruiting someone who has fill and finish experience.

so my guess is still with novavax, we probably need to wait for an update on the raw material shortage and the TGA approval.

I know it's not as excited as building and mRNA factory but still it's significant for idt.